JNJ Johnson & Johnson Inc.: רווח למניה ב-12 החודשים האחרונים

Despite the pressure of litigation and pricing reforms in the US, Johnson & Johnson (JNJ) maintains resilience. Comparing the current YoY ttm net income per share growth on GURU.Markets, we see that -35.80 represents a fresh level value. This confirms the effectiveness of the consumer sector spin-off by experienced management and global scalability driven by patents that ensure low marginal production costs.

Exclusive medical technologies at Johnson & Johnson (JNJ) allow the company to maintain high margins and ensure stable demand. By analyzing the annual change in net income per share over a rolling period, one can assess the effectiveness of this strategy. This indicator measures the growth rate of equity income over the last 12 months, reflecting the actual scaling of the business. Positive dynamics confirm the resilience of fundamental indicators, minimizing the risk of overpaying for the asset.